KR102717656B1 - 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 - Google Patents

종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 Download PDF

Info

Publication number
KR102717656B1
KR102717656B1 KR1020197033590A KR20197033590A KR102717656B1 KR 102717656 B1 KR102717656 B1 KR 102717656B1 KR 1020197033590 A KR1020197033590 A KR 1020197033590A KR 20197033590 A KR20197033590 A KR 20197033590A KR 102717656 B1 KR102717656 B1 KR 102717656B1
Authority
KR
South Korea
Prior art keywords
isvd
seq
polypeptide
lrp5
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033590A
Other languages
English (en)
Korean (ko)
Other versions
KR20200011933A (ko
Inventor
빗토리아 진잘라
클라우스-페터 쿠엔켈레
마리-앙게 부이쎄
카렌 크로미
스테파니 스타엘렌스
베아트리스 스트룹베
Original Assignee
베링거 인겔하임 인터내셔날 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102717656(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베링거 인겔하임 인터내셔날 게엠베하 filed Critical 베링거 인겔하임 인터내셔날 게엠베하
Publication of KR20200011933A publication Critical patent/KR20200011933A/ko
Application granted granted Critical
Publication of KR102717656B1 publication Critical patent/KR102717656B1/ko
Assigned to 아블린쓰 엔.브이. reassignment 아블린쓰 엔.브이. 권리의 전부이전등록 Assignors: 베링거 인겔하임 인터내셔날 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197033590A 2017-05-31 2018-05-30 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 Active KR102717656B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17173782.8 2017-05-31
EP17173782 2017-05-31
PCT/EP2018/064295 WO2018220080A1 (en) 2017-05-31 2018-05-30 Polypeptides antagonizing wnt signaling in tumor cells

Publications (2)

Publication Number Publication Date
KR20200011933A KR20200011933A (ko) 2020-02-04
KR102717656B1 true KR102717656B1 (ko) 2024-10-14

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033590A Active KR102717656B1 (ko) 2017-05-31 2018-05-30 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드

Country Status (26)

Country Link
US (3) US11033636B2 (enExample)
EP (1) EP3630816B1 (enExample)
JP (1) JP7216024B2 (enExample)
KR (1) KR102717656B1 (enExample)
CN (1) CN110637030B (enExample)
AR (1) AR111840A1 (enExample)
AU (1) AU2018276409B2 (enExample)
BR (1) BR112019022729A2 (enExample)
CA (1) CA3060401A1 (enExample)
CL (1) CL2019003419A1 (enExample)
CO (1) CO2019012329A2 (enExample)
EA (1) EA201992808A1 (enExample)
ES (1) ES2979194T3 (enExample)
HU (1) HUE067691T2 (enExample)
IL (1) IL270854B2 (enExample)
MA (1) MA48760A (enExample)
MX (1) MX2019014331A (enExample)
MY (1) MY200744A (enExample)
NZ (1) NZ758031A (enExample)
PE (1) PE20200610A1 (enExample)
PH (1) PH12019502602A1 (enExample)
PL (1) PL3630816T3 (enExample)
TW (1) TWI887192B (enExample)
UA (1) UA125761C2 (enExample)
WO (1) WO2018220080A1 (enExample)
ZA (1) ZA201906610B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033636B2 (en) * 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
CN118271444A (zh) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
AU2020221797A1 (en) * 2019-02-11 2021-08-12 Surrozen Operating, Inc. Modulation of WNT signalling in ocular disorders
US11578129B2 (en) * 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy
US20230183336A1 (en) * 2019-08-14 2023-06-15 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
KR102920873B1 (ko) * 2021-07-13 2026-02-02 인제대학교 산학협력단 NEURL 유전자, 이를 포함하는 발현벡터 또는 NEURL 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
CN117897408A (zh) * 2021-08-10 2024-04-16 热生物制品有限公司 新型tim-4结合剂的生成和表征
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体
CN120424217B (zh) * 2025-04-30 2026-03-06 立凌生物制药(苏州)有限公司 靶向b细胞抗原和t细胞抗原的多特异性抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP4271735B2 (ja) 1997-04-15 2009-06-03 メルク アンド カンパニー，インコーポレイティド 新規のｌｄｌ−レセプター
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
EP1395285A4 (en) 2001-05-17 2005-06-01 Genome Therapeutics Corp REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
EP1558645B1 (en) 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
WO2007027509A2 (en) 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
US20110091462A1 (en) 2008-03-05 2011-04-21 Ablynx N.V. Novel antigen binding dimer-complexes, methods of making and uses thereof
CA2721202A1 (en) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
EP2531523A1 (en) 2010-02-05 2012-12-12 Ablynx N.V. Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
PH12012501744A1 (en) 2010-03-03 2021-08-09 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
KR101899835B1 (ko) * 2010-03-24 2018-09-19 제넨테크, 인크. 항-ｌｒｐ６ 항체
SG185416A1 (en) * 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MX2012012927A (es) 2010-05-06 2013-05-01 Novartis Ag Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
CN103501799A (zh) * 2011-01-28 2014-01-08 莱兰斯坦福初级大学评议会 Wnt组合物及其使用方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
CA3141978A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
US8883735B2 (en) 2011-11-04 2014-11-11 Novartis Ag Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs
SG10201601747XA (en) * 2012-01-18 2016-04-28 Genentech Inc Anti-LRP5 Antibodies And Methods Of Use
AU2016357460B2 (en) * 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
PT3383425T (pt) * 2015-12-04 2020-10-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizam a sinalização wnt em células tumorais
US11033636B2 (en) * 2017-05-31 2021-06-15 Boehringer Ingelheim International Gmbh Polypeptides antagonizing Wnt signaling in tumor cells
US11578129B2 (en) * 2019-03-29 2023-02-14 Boehringer Ingelheim International Gmbh LRP5 and PD-1 antagonist anticancer combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 2010, Vol. 107(35), pp. 15473-15478*

Also Published As

Publication number Publication date
KR20200011933A (ko) 2020-02-04
CN110637030A (zh) 2019-12-31
ES2979194T3 (es) 2024-09-24
IL270854B2 (en) 2023-02-01
JP2020521478A (ja) 2020-07-27
NZ758031A (en) 2026-03-27
EA201992808A1 (ru) 2020-05-14
AU2018276409B2 (en) 2025-02-27
HUE067691T2 (hu) 2024-11-28
IL270854A (en) 2020-01-30
US20220362393A1 (en) 2022-11-17
US12285493B2 (en) 2025-04-29
US20180344868A1 (en) 2018-12-06
IL270854B (en) 2022-10-01
ZA201906610B (en) 2025-12-17
CN110637030B (zh) 2024-06-11
MA48760A (fr) 2020-04-08
US20250345448A1 (en) 2025-11-13
MY200744A (en) 2024-01-13
EP3630816A1 (en) 2020-04-08
AR111840A1 (es) 2019-08-21
JP7216024B2 (ja) 2023-01-31
MX2019014331A (es) 2020-01-27
AU2018276409A1 (en) 2019-10-31
CL2019003419A1 (es) 2020-03-27
TW201906858A (zh) 2019-02-16
PH12019502602A1 (en) 2020-06-08
CA3060401A1 (en) 2018-12-06
PL3630816T3 (pl) 2024-08-05
PE20200610A1 (es) 2020-03-10
TWI887192B (zh) 2025-06-21
CO2019012329A2 (es) 2020-01-17
US11033636B2 (en) 2021-06-15
BR112019022729A2 (pt) 2020-05-19
WO2018220080A1 (en) 2018-12-06
UA125761C2 (uk) 2022-06-01
EP3630816C0 (en) 2024-03-20
EP3630816B1 (en) 2024-03-20

Similar Documents

Publication Publication Date Title
US11952418B2 (en) Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
US12285493B2 (en) Polypeptides antagonizing Wnt signaling in tumor cells
HK40040630A (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
CA3006235C (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
HK1255725B (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
EA046752B1 (ru) Полипептиды, препятствующие передаче wnt сигналов в опухолевых клетках
EA040170B1 (ru) БИПАРАТОПНЫЕ ПОЛИПЕПТИДЫ-АНТАГОНИСТЫ ПЕРЕДАЧИ СИГНАЛА Wnt В ОПУХОЛЕВЫХ КЛЕТКАХ

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)